Chapter 2. Antimicrobial Resistance

Retail Meat Surveillance

Key Findings

Beef

Escherichia Coli (n = 362)

As in previous years, resistance levels (= 1%) of category I β-lactam amoxicillin-clavulanic acid, ceftriaxone, and ceftiofur remained low in beef E. coli isolates in 2012 (Table 9). No ciprofloxacin resistance was observed in 2012 (Table 9). One isolate (1%, 1/107) from Ontario was resistant to azithromycin (Table 9).

Chicken

Salmonella (n = 307)

Across all provincesFootnote 8 sampled, the top 3 chicken Salmonella serovars were S. Heidelberg, S. Kentucky, and S. Enteritidis. Regional differences in serovar distribution were observed in 2012 with S. Enteritidis being the most common serovar in both British Columbia (34%, 18/53) and Saskatchewan (30%, 14/46) unlike Ontario and Québec where the most common serovar was S. Heidelberg (41%, 42/102 and 40%, 40/106 respectively) (Table 10). No S. Enteritidis was recovered in Québec.

All S. Enteritidis isolates were susceptible to all antimicrobials tested in 2012. No ciprofloxacin resistance was observed in any serotype in 2012 (Table 10). Nalidixic acid resistance was observed in 2 S. Kentucky isolates (4%, 2/53) from British Columbia (Table 10); previously nalidixic acid resistance has only been observed in 2 isolates (S. Hadar and S. 4,[5],12:i-) from Saskatchewan in 2005.

Category I β-lactam (amoxicillin-clavulanic acid, ceftriaxone, ceftiofur) resistance levels (26%, 80/307) remained similar to levels in 2011 (30%, 108/361). Resistance to ceftiofur (23%, 23/102) was significantly lower in 2012 than 2004 (46%, 25/54) in Ontario (Figure 11). Although resistance to ceftiofur (28%, 30/106) was significantly lower in 2012 than 2003 (50%, 14/28) in Québec, ceftiofur resistance in Québec was significantly higher in 2012 compared to 2006 (9%, 3/33) (Figure 11).


Escherichia Coli (n = 373)

No ciprofloxacin resistance was observed in chicken E. coli isolates in 2012 (Table 11). Resistance levels of category I β-lactam amoxicillin-clavulanic acid, ceftriaxone, and ceftiofur remain similar to those in 2011. Resistance to ceftiofur was significantly higher in 2012 (22%, 14/64) than 2005 (4%, 3/82) in Saskatchewan (Figure 12). Resistance to ceftiofur was significantly higher in 2012 (25%, 32/128) than 2006 (6%, 8/135) in Québec (Figure 12). One isolate (1%, 1/128) from Québec was resistant to azithromycin (Table 11).

Campylobacter (n = 280)

Low-level (3%, 3/88) of telithromycin resistance was observed in Campylobacter isolates from Ontario in 2012 (Table 12); this is similar to levels in recent previous years.

In 2012, ciprofloxacin resistance continues to decline in British Columbia (8%, 6/73) and remains at a similar level in Saskatchewan (5%, 2/40) compared to 2011 (4%, 1/25) (Figure 13). In isolates from Ontario, ciprofloxacin resistance has significantly increased in 2012 (16%, 14/88) compared to 2011 (6%, 4/71) and 2003 (4%, 3/78) (Figure 13). Resistance to azithromycin was significantly lower in 2012 (8%, 6/79) than 2003 (22%, 21/94) in Québec (Figure 13).

Pork

Escherichia Coli (n = 193)

Recovery of E. coli from retail pork continues to decline overall and remains relatively low (Table 25).

No key findings were found with respect to antimicrobial resistance.

Turkey

In 2012, no statistical temporal analyses were performed for retail ground turkey samples. Additionally, no temporal variation figures were presented as 2012 was the first year for retail ground turkey sampling.

Salmonella (n = 140)

The distribution of Salmonella serovars varies by province in the first full year of retail surveillance of ground turkey (Table 14).

No ciprofloxacin or nalidixic acid resistance was observed (Table 14). One (2%, 1/44) S. Indiana isolate from Ontario was resistant to 6 antimicrobial classes (Table 14) and presented the ACKSSuT-A2C-AZM-CRO-GEN-SXT resistance pattern.

Escherichia Coli (n = 504)

One (1%, 1/152) retail turkey isolate of E. coli from Ontario was resistant to 7 classes of antimicrobials tested (Table 15) and had the following resistance pattern: ACKSSuT-A2C-AZM-CRO-CIP-GEN-NAL-SXT.

Campylobacter (n = 74)

Two isolates (10%, 2/20) from Ontario were resistant to telithromycin in 2012 (Table 16). Ciprofloxacin resistance was observed in 21% (7/33) of isolates from British Columbia and 1 (1/6) isolate from Saskatchewan (Table 16).

Multiclass Resistance

Table 9. Number of antimicrobial classes in resistance patterns of Escherichia coli from beef
Province or region Number (%) of isolates Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides β-lactams Folate pathway inhibitors Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN KAN STR AMP AMC CRO FOX TIO SSS SXT AZM CHL CIP NAL TET
British Columbia 70 (19.3) 46 7 15 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 15 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 2 24
Saskatchewan 78 (21.5) 62 6 10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 8 14
Ontario 110 (30.4) 73 13 18 5 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 18 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 33
Québec 104 (28.7) 86 7 10 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 16

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.

Table 10. Number of antimicrobial classes in resistance patterns of Salmonella from chicken
Province or region / serovar Numbers (%)
of isolates
Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides β-lactams Folate pathway inhibitors Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN KAN STR AMP AMC CRO FOX TIO SSS SXT AZM CHL CIP NAL TET
British Columbia                                          
Enteritidis 18 (34) 18
Kentucky 15 (28.3) 1 12 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 13 13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 14
Heidelberg 7 (13.2) 1 6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 6 6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 6
Hadar 5 (9.4) 4 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1
Infantis 2 (3.8) 2
Mbandaka 2 (3.8) 1 1 1
Less common serovars 4 (7.5) 2 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 2 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 2
Total 53 (100) 28 10 13 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21 21 21 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19 21 2 16
Saskatchewan                                          
Enteritidis 14 (30.4) 14
Kentucky 10 (21.7) 2 3 5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 5 5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 5 5
Heidelberg 5 (10.9) 5
Infantis 4 (8.7) 3 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1
Thompson 4 (8.7) 4
Hadar 2 (4.3) 1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1
Schwarzengrund 2 (4.3) 2
Typhimurium 2 (4.3) 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 2 2 2
Livingstone var.14+ 1 (2.2) 1
Mbandaka 1 (2.2) 1 1
Senftenberg 1 (2.2) 1
Total 46 (100) 33 5 6 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 6 6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 6 2 2 9
Ontario                                          
Heidelberg 42 (41.2) 26 16 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 12 12 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12 12 1
Kentucky 34 (33.3) 11 3 20 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 9 9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 9 21
Enteritidis 3 (2.9) 3
Kiambu 3 (2.9) 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 3
Less common serovars 20 (19.6) 12 3 3 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 2 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 2 3 1 5
Total 102 (100) 52 22 26 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32 23 23 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21 23 3 1 30
Québec                                          
Heidelberg 40 (37.7) 27 13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 12 12 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 12
Kentucky 32 (30.2) 5 27 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 11 11 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 11 27
Thompson 13 (12.3) 12 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1
I 4,[5],12:r:- 3 (2.8) 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 3 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 3
Less common serovars 18 (17) 9 2 6 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 3 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 3 6 1 6
Total 106 (100) 53 19 33 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31 30 30 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29 30 6 1 33

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Serovars represented by less than 2% of isolates were classified as "Less common serovars".

Table 11. Number of antimicrobial classes in resistance patterns of Escherichia coli from chicken
Province or region Number (%) of isolates Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides β-lactams Folate pathway inhibitors Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN KAN STR AMP AMC CRO FOX TIO SSS SXT AZM CHL CIP NAL TET
British Columbia 74 (19.8) 19 15 23 17 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44 32 30 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30 29 26 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 8 3 31
Saskatchewan 64 (17.2) 23 17 18 6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18 15 14 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 14 13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 5 23
Ontario 107 (28.7) 32 19 47 9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47 21 20 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21 20 29 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 1 2 52
Québec 128 (34.3) 29 19 52 28 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56 34 34 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34 32 63 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 5 2 76

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.

Table 12. Number of antimicrobial classes in resistance patterns of Campylobacter from chicken
Province or region / species Numbers (%)
of isolates
Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides Ketolides Lincosamides Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN TEL CLI AZM ERY FLR CIP NAL TET
British Columbia                              
Campylobacter jejuni 66 (90.4) 48 16 2 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 17
Campylobacter coli 7 (9.6) 3 3 1 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 2
Total 73 (100) 51 19 3 6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 19
Saskatchewan
Campylobacter jejuni 36 (90) 17 16 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 19
Campylobacter coli 3 (7.5) 2 1 1
Campylobacter spp. 1 (2.5) 1
Total 40 (100) 20 17 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 20
Ontario
Campylobacter jejuni 75 (85.2) 34 29 12 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 38
Campylobacter coli 10 (11.4) 5 2 2 1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 4
Campylobacter spp. 3 (3.4) 3 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3
Total 88 (100) 39 34 14 1 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 14 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 42
Québec
Campylobacter jejuni 76 (96.2) 25 45 6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 49
Campylobacter coli 3 (3.8) 2 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1
Total 79 (100) 27 45 7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 50
Maritimes
Campylobacter jejuni 8 (88.9) 5 3 3
Campylobacter coli 1 (11.1) 1 1
Total 9 (100) 5 4 4

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Campylobacter spp. include unidentified species, some of which may be intrinsically resistant to nalidixic acid.

Table 13. Number of antimicrobial classes in resistance patterns of Escherichia coli from pork
Province or region Number (%) of isolates Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides β-lactams Folate pathway inhibitors Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN KAN STR AMP AMC CRO FOX TIO SSS SXT AZM CHL CIP NAL TET
British Columbia 37 (19.2) 26 4 5 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 4 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 4 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 9
Saskatchewan 26 (13.5) 16 2 7 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 2 9
Ontario 86 (44.6) 33 13 32 8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25 2 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 1 20 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 7 50
Québec 44 (22.8) 21 4 13 6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 17 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 21

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.

Table 14. Number of antimicrobial classes in resistance patterns of Salmonella from turkey
Province or region / serovar Numbers (%)
of isolates
Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides β-lactams Folate pathway inhibitors Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN KAN STR AMP AMC CRO FOX TIO SSS SXT AZM CHL CIP NAL TET
British Columbia                                          
Enteritidis 7 (25.9) 7                                      
Kentucky 7 (25.9)     7         Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6             7
Hadar 5 (18.5)     5         Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5                       5
Heidelberg 3 (11.1) 1 2             Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2              
Agona 2 (7.4)     1 1       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2   Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2   Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 2           2
Johannesburg 1 (3.7) 1                                      
Newport 1 (3.7) 1                                      
Schwarzengrund 1 (3.7) 1                                      
Total 27 (100) 11 2 13 1       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 2           14
Saskatchewan                                          
Derby 3 (16.7)     3         Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3           3           3
Agona 2 (11.1)     1 1   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 2           2
Hadar 2 (11.1)     2     Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2           2           2
Heidelberg 2 (11.1) 1 1                                   1
Meleagridis 2 (11.1) 2                                      
Alachua 1 (5.6) 1                                      
Kentucky 1 (5.6)     1         Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1                       1
Mbandaka var.14+ 1 (5.6)   1                                   1
Reading 1 (5.6) 1                                      
Schwarzengrund 1 (5.6)     1         Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1           1           1
Typhimurium var. 5- 1 (5.6)       1       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1         1     1     1
Uganda 1 (5.6) 1                                      
Total 18 (100) 6 2 8 2   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 9     1     12
Ontario                                          
Heidelberg 14 (31.8) 11 2 1         Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3              
Enteritidis 5 (11.4) 5                                      
Saintpaul 5 (11.4) 5                                      
Infantis 3 (6.8) 1 1   1   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 1     1     1
Schwarzengrund 3 (6.8) 3                                      
Hadar 2 (4.5)     2         Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2                       2
Indiana 2 (4.5)       1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 2     2
Typhimurium 2 (4.5) 1     1     Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1         1     1     1
Worthington 2 (4.5) 1 1             Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1              
Albany 1 (2.3)     1     Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1     Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1              
I 4,[5],12:i:- 1 (2.3) 1                                      
I 6,7:-:1,5 1 (2.3) 1                                      
Johannesburg 1 (2.3) 1                                      
Kentucky 1 (2.3)     1         Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1                       1
Typhimurium var. 5- 1 (2.3)       1       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1         1     1     1
Total 44 (100) 30 4 5 4 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 11 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 5     8
Québec                                          
Heidelberg 9 (17.6)   4 3 2       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 2           6
Saintpaul 9 (17.6) 9                                      
Agona 6 (11.8) 1 5             Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5              
Muenster 5 (9.8) 3   2         Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2                      
Schwarzengrund 5 (9.8) 2   3     Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3           3           2
Worthington 3 (5.9) 2 1             Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1              
Kentucky 2 (3.9)     2         Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1             2
Kiambu 2 (3.9)     2         Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2         2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2          
Liverpool 2 (3.9) 2                                      
Thompson 2 (3.9) 2                                      
Less common serovars 6 (11.8) 2 1 3         Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 1           2
Total 51 (100) 23 11 15 2   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15 8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2         12

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Serovars represented by less than 2% of isolates were classified as "Less common serovars".

Table 15. Number of antimicrobial classes in resistance patterns of Escherichia coli from turkey
Province or region Number (%) of isolates Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides β-lactams Folate pathway inhibitors Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN KAN STR AMP AMC CRO FOX TIO SSS SXT AZM CHL CIP NAL TET
British Columbia 101 (20.0) 35 17 41 8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31 16 14 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 13 26 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 47
Saskatchewan 81 (16.1) 30 12 31 8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20 4 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 3 20 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 42
Ontario 152 (30.2) 49 34 49 19 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47 17 14 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 13 42 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 8 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 90
Québec 170 (33.7) 55 27 67 21 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64 21 19 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20 19 49 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20 10 99

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.

Table 16. Number of antimicrobial classes in resistance patterns of Campylobacter from turkey
Province or region / species Numbers (%)
of isolates
Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides Ketolides Lincosamides Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN TEL CLI AZM ERY FLR CIP NAL TET
British Columbia                              
Campylobacter jejuni 26 (78.8) 20 3 3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 6
Campylobacter coli 7 (21.2) 4 3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 6
Total 33 (100) 20 7 6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 12
Saskatchewan
Campylobacter jejuni 6 (100) 2 3 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 4
Total 6 (100) 2 3 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 4
Ontario
Campylobacter jejuni 12 (60) 1 10 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 10
Campylobacter coli 8 (40) 2 5 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 5
Total 20 (100) 3 15 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 15
Québec
Campylobacter jejuni 14 (93.3) 3 11 11
Campylobacter coli 1 (6.7) 1
Total 15 (100) 4 11 11

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.

Temporal Antimicrobial Resistance Summary

Figure 10. Temporal variations in resistance of Escherichia coli isolates from beef

Temporal variations in resistance of Escherichia coli isolates from beef
Figure 10. Temporal variations in resistance of Escherichia coli isolates from beef
Province British Columbia   Saskatchewan   Ontario   Québec   Maritimes
Year '07 '08 '09 '10 '11 '12 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '08 '09 '10 '11
Number of isolates 49 88 79 64 57 70 120 123 118 134 135 107 54 78 101 191 184 189 187 185 195 123 161 110 84 137 126 109 147 126 108 101 91 104 39 135 126 110
Antimicrobial

For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas).
Due to unforeseen and lengthy delays in retail sampling in the Maritimes in 2012, data are not presented for this year in the interest of precision. Data for this region will be presented again in 2013.
The Maritimes is a region including the provinces of New Brunswick, Nova Scotia, and Prince Edward Island.

Ampicillin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 6% 3% 6% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 1% 3% 1% 0% 4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8% 5% 3% 4% 3% 6% 3% 4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% 4% 6% 4% 3% 2% 6% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%   3% 6% 2% 1%
Ceftiofur Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 2% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 1% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 1% 0% 1% 0% 1% 1% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 2% 1% 0% 1% 1% 1% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 3% 1% 1% 0%
Gentamicin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 1% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 0% 1% 1% 2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 0% 1% 0% 0% 0% 0% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 0%
Nalidixic acid Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 0% 0% 2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 1% 0% 1% 1% 0% 0% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 1% 0% 0% 0% 0% 1% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% 0% 0% 0% 1%
Streptomycin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 9% 4% 8% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.20% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% 2% 1% 5% 3% 6% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% 6% 5% 4% 3% 11% 13% 11% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% 9% 4% 6% 7% 7% 9% 8% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6% 5% 7% 2% 3%
Tetracycline Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% 23% 10% 16% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.34% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% 9% 8% 20% 13% 14% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.18% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.23% 19% 17% 15% 14% 21% 23% 18% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.30% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19% 15% 17% 20% 15% 17% 12% 15% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.15% 18% 19% 12% 11%
Trimethoprim-sulfamethoxazole Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% 0% 4% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 0% 0% 1% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 2% 1% 2% 2% 3% 4% 6% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 2% 3% 2% 2% 1% 2% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 3% 2% 2% 1%
Temporal variations in resistance of Salmonella isolates from chicken
Figure 11. Temporal variations in resistance of Salmonella isolates from chicken
Province British Columbia   Saskatchewan   Ontario   Québec   Maritimes
Year '07 '08 '09 '10 '11 '12 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '08 '09 '10 '11
Number of isolates 18 47 59 56 64 53 21 25 43 64 71 42 29 46 26 54 26 36 172 139 142 90 119 102 28 53 26 33 113 120 105 116 100 106 12 96 77 49
Antimicrobial

For the temporal analyses by province/region, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (bold numbers). The presence of underlined areas indicates significant differences (P ≤ 0.05) for a given province/region and antimicrobial.
Additional temporal analyses for ampicillin and ceftiofur were conducted for Salmonella isolates from Ontario and Québec. These two antimicrobials, provinces, and years (2004 and 2006) were selected due to a change in ceftiofur use practices by Québec chicken hatcheries in early 2005 and in 2007 (start and end of the voluntary period of withdrawal). Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results are indicated by underlined numbers.
Due to unforeseen and lengthy delays in retail sampling in the Maritimes in 2012, data are not presented for this year in the interest of precision. Data for this region will be presented again in 2013.
The Maritimes is a region including the provinces of New Brunswick, Nova Scotia, and Prince Edward Island.

Ampicillin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39% 28% 27% 25% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.38% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.40%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% 12% 23% 9% 24% 19% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19% 52% 19% 17% 16% 14% 32% 29% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.33% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.31%   Significant differences (P ≤ 0.05) for a given antimicrobial.61% 49% 23% 15% 16% 21% 39% 34% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.30% Significant differences (P ≤ 0.05) for a given antimicrobial.29%   17% 29% 23% 29%
Ceftiofur Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.33% 23% 27% 25% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.38% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.40% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 4% 2% 5% 15% 7% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.12% Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.46% 15% 14% 11% 10% 24% 24% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year. Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.23% Significant differences (P ≤ 0.05) for a given antimicrobial.50% 40% 15% Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.9% 9% 15% 20% 25% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29% Significant differences (P ≤ 0.05) for a given antimicrobial. Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.28% 17% 23% 21% 29%
Gentamicin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% 0% 0% 0% 2% 1% 1% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% 2% 0% 0% 3% 2% 1% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% 8% 1% 0% 0%
Nalidixic acid Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% 0% 0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 0%
Streptomycin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% 30% 14% 27% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.20% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.26% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.43% 20% 37% 36% 23% 24% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.31% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% 4% 12% 25% 31% 32% 35% 29% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.30% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.21% 23% 8% 39% 37% 31% 30% 25% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.50% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.30% 17% 27% 25% 41%
Tetracycline Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17% 30% 15% 29% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.22% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.30% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.52% 32% 35% 36% 27% 17% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.20% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 4% 8% 25% 34% 36% 35% 33% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.31% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.21% 23% 8% 39% 37% 35% 30% 24% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.53% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.31% 8% 29% 26% 43%
Trimethoprim-sulfamethoxazole Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 2% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 2% 0% 3% 1% 1% 1% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 0% 0% 3% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 3% 0%
Temporal variations in resistance of Escherichia coli isolates from chicken
Figure 12. Temporal variations in resistance of Escherichia coli isolates from chicken
Province British Columbia   Saskatchewan   Ontario   Québec   Maritimes
Year '07 '08 '09 '10 '11 '12 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '08 '09 '10 '11
Number of isolates 42 70 70 75 70 74 82 85 75 92 90 71 38 64 136 150 145 152 157 150 155 100 137 107 111 158 142 135 128 131 126 138 133 128 37 185 175 171
Antimicrobial

For the temporal analyses by province/region, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given province/region and antimicrobial.
Additional temporal analyses for ampicillin and ceftiofur were conducted for E. coli isolates from Ontario and Québec. These two antimicrobials, provinces, and years (2004 and 2006) were selected due to a change in ceftiofur use practices by Québec chicken hatcheries in early 2005 and in 2007 (start and end of the voluntary period of withdrawal). Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results are indicated by underlined numbers.
Due to unforeseen and lengthy delays in retail sampling in the Maritimes in 2012, data are not presented for this year in the interest of precision. Data for this region will be presented again in 2013.
The Maritimes is a region including the provinces of New Brunswick, Nova Scotia, and Prince Edward Island.

Ampicillin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.60% 63% 61% 63% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.66% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.59%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24% 31% 35% 40% 36% 35% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.42% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.35% 39% 33% 42% 39% 39% 41% 39% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.43% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.44%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.50% 52% 49% 35% 34% 33% 41% 54% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.38% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.44%   30% 42% 40% 52%
Ceftiofur Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29% 49% 41% 44% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39% Significant differences (P ≤ 0.05) for a given antimicrobial.4% 6% 13% 20% 22% 20% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24% Significant differences (P ≤ 0.05) for a given antimicrobial.22% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.18% 21% 17% 22% 22% 24% 21% 21% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.32% 34% 25% Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.6% 13% 18% 19% 27% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.20% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year. Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.25% 19% 27% 18% 33%
Gentamicin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 6% 1% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.12% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6% 6% 11% 9% 8% 6% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% 5% 7% 6% 13% 12% 7% 18% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.12% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17% 10% 11% 21% 24% 21% 27% 18% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.21% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24% 5% 15% 14% 18%
Nalidixic acid Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% 4% 7% 7% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% 4% 5% 7% 4% 10% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 1% 1% 3% 3% 4% 3% 2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 5% 2% 1% 3% 8% 3% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 0% 4% 3% 6%
Streptomycin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.21% 31% 34% 21% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.36% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.26% 33% 32% 29% 37% 27% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.42% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.36% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.32% 33% 26% 26% 31% 33% 41% 36% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.34% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.48% 46% 36% 43% 37% 39% 56% 43% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.43% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.45% 30% 36% 37% 39%
Tetracycline Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.45% 46% 46% 45% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.42% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.48% 47% 44% 48% 51% 41% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.42% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.36% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.51% 52% 46% 41% 48% 40% 49% 41% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.42% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.49% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.57% 53% 43% 49% 48% 45% 60% 57% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.52% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.59% 41% 40% 52% 46%
Trimethoprim-sulfamethoxazole Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17% 6% 3% 4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 1% 4% 3% 6% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% 4% 3% 4% 4% 7% 11% 10% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.12% 11% 10% 6% 12% 15% 16% 18% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.16% 16% 15% 20% 12%
Temporal variations in resistance of Campylobacter isolates from chicken
Figure 13. Temporal variations in resistance of Campylobacter isolates from chicken
Province British Columbia   Saskatchewan   Ontario   Québec   Maritimes
Year '07 '08 '09 '10 '11 '12 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '09 '10 '11
Number of isolates 28 50 77 70 71 73 52 51 49 40 48 36 25 40 78 140 120 105 117 120 101 64 71 88 94 158 103 100 59 54 52 63 57 79 47 68 53
Antimicrobial

For the temporal analyses by province/region, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given province/region and antimicrobial.
Due to unforeseen and lengthy delays in retail sampling in the Maritimes in 2012, data are not presented for this year in the interest of precision. Data for this region will be presented again in 2013.
Although routine retail surveillance began in the Maritime region in 2008, no results are displayed for that year due to concerns regarding harmonization of laboratory methods.
The Maritimes is a region including the provinces of New Brunswick, Nova Scotia, and Prince Edward Island.
Due to unforeseen and lengthy delays in retail sampling in the Maritimes in 2012, data are not presented for this year in the interest of precision. Data for this region will be presented again in 2013.
The Maritimes is a region including the provinces of New Brunswick, Nova Scotia, and Prince Edward Island.

Azithromycin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 2% 2% 0% 0% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% 8% 5% 4% 2% 8% 5% 9% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7%   Significant differences (P ≤ 0.05) for a given antimicrobial.22% 16% 13% 9% 10% 11% 8% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% Significant differences (P ≤ 0.05) for a given antimicrobial.8%   6% 0% 0%
Ciprofloxacin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% 8% 29% 17% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6% 2% 6% 10% 15% 11% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% Significant differences (P ≤ 0.05) for a given antimicrobial.4% 2% 3% 3% 1% 4% 1% 5% Significant differences (P ≤ 0.05) for a given antimicrobial.6% Significant differences (P ≤ 0.05) for a given antimicrobial.16% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% 3% 2% 2% 14% 0% 0% 2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% 4% 4% 9%
Gentamicin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 0% 0% 0% 0% 1% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 0% 0% 0% 0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0%
Telithromycin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 2% 2% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 4% 1% 4% 4% 6% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 1% 5% 2% 6% 5% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 6% 0% 0%
Tetracycline Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39% 32% 53% 43% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.34% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.26% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.54% 35% 39% 45% 60% 61% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.56% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.50% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.58% 47% 61% 55% 57% 49% 39% 53% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.46% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.48% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.70% 79% 70% 66% 54% 56% 62% 51% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.47% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.63% 53% 43% 55%
Temporal variations in resistance of Escherichia coli isolates from pork
Figure 14. Temporal variations in resistance of Escherichia coli isolates from pork
Province British Columbia   Saskatchewan   Ontario   Québec   Maritimes
Year '07 '08 '09 '10 '11 '12 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '08 '09 '10 '11
Number of isolates 23 44 38 31 49 37 48 49 38 42 29 17 10 26 91 199 179 182 172 155 136 84 155 86 61 107 78 58 64 60 41 47 122 44 17 81 71 95
Antimicrobial

For the temporal analyses by province/region, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas).
Due to unforeseen and lengthy delays in retail sampling in the Maritimes in 2012, data are not presented for this year in the interest of precision. Data for this region will be presented again in 2013.
The Maritimes is a region including the provinces of New Brunswick, Nova Scotia, and Prince Edward Island.

Ampicillin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13% 23% 8% 23% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.16% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 6% 5% 12% 10% 18% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.20% 23% 21% 21% 23% 17% 18% 11% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.21% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.20% 19% 12% 19% 20% 18% 20% 21% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.35% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.18%   18% 12% 23% 26%
Ceftiofur Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 7% 0% 13% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 3% 7% 3% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 1% 1% 1% 1% 1% 0% 2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 2% 3% 0% 0% 3% 0% 4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 3% 2%
Gentamicin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 5% 5% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 2% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 3% 1% 1% 1% 3% 1% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 3% 1% 3% 2% 2% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% 0% 2% 3% 2%
Nalidixic acid Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 2% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 1% 0% 0% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 0% 5% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 0% 1% 1% 0%
Streptomycin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13% 23% 18% 6% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.18% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.14% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17% 10% 5% 14% 17% 18% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.16% 26% 20% 20% 21% 14% 24% 17% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.30% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28% 21% 17% 19% 23% 13% 17% 23% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.23% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.36% 12% 25% 15% 36%
Tetracycline Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.35% 45% 34% 32% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.27% 31% 24% 29% 34% 35% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.60% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.35% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.55% 55% 49% 48% 46% 38% 35% 33% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.38% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.58% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.48% 36% 33% 36% 45% 35% 27% 34% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.58% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.48% 41% 48% 59% 58%
Trimethoprim-sulfamethoxazole Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 7% 8% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 2% 5% 0% 3% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% 7% 7% 4% 5% 7% 7% 5% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% 7% 6% 7% 3% 10% 10% 11% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.15% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% 12% 7% 13% 14%

Minimum Inhibitory Concentrations

More details on how to interpret the minimum inhibitory concentrations (MICs) tables are provided in the CIPARS Annual Report 2012 – Chapter 1. Design and Methods.

Table 17. Distribution of minimum inhibitory concentrations among Escherichia coli from beef
  Antimicrobial Province / region n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0,015 0,03 0,06 0,12 0,25 0,5 1 2 4 8 16 32 64 128 256 >256
I Amoxicillin-clavulanic acid British Columbia 70 4 4 1.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.7 Table 17 - Footnote1  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4
Saskatchewan 78 4 4 1.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.7 Table 17 - Footnote1  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3
Ontario 110 4 8 0.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.2 Table 17 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9 Table 17 - Footnote2
Québec 104 4 4 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.8 Table 17 - Footnote1
Ceftiofur British Columbia 70 0.25 0.50 1.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.3  Table 17 - Footnote1  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4
Saskatchewan 78 0.25 0.50 1.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46.2  Table 17 - Footnote1  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3
Ontario 110 0.25 0.50 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Table 17 - Footnote1  Table 17 - Footnote2
Québec 104 0.25 0.50 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.5  Table 17 - Footnote1  Table 17 - Footnote2
Ceftriaxone British Columbia 70 <=0.25 <=0.25 1.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.6  Table 17 - Footnote1  Table 17 - Footnote2 1.4
Saskatchewan 78 <=0.25 <=0.25 1.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.7  Table 17 - Footnote1  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3
Ontario 110 <=0.25 <=0.25 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Table 17 - Footnote1  Table 17 - Footnote2
Québec 104 <=0.25 <=0.25 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0  Table 17 - Footnote1  Table 17 - Footnote2
Ciprofloxacin British Columbia 70 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0  Table 17 - Footnote1  Table 17 - Footnote2
Saskatchewan 78 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0  Table 17 - Footnote1  Table 17 - Footnote2
Ontario 110 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.2  Table 17 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9  Table 17 - Footnote2
Québec 104 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.9  Table 17 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0  Table 17 - Footnote2
II Ampicillin British Columbia 70 2 4 4.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4  Table 17 - Footnote1  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.3
Saskatchewan 78 2 4 2.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.5  Table 17 - Footnote1  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.6
Ontario 110 2 4 8.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.4  Table 17 - Footnote1  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8.2
Québec 104 2 4 2.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.0  Table 17 - Footnote1 1.0  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.9
Azithromycin British Columbia 70 4 4 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4  Table 17 - Footnote2
Saskatchewan 78 4 4 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.1  Table 17 - Footnote2
Ontario 110 4 4 0.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9 Table 17 - Footnote2
Québec 104 4 4 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.7  Table 17 - Footnote2
Cefoxitin British Columbia 70 4 4 1.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 Table 17 - Footnote1  Table 17 - Footnote2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4
Saskatchewan 78 4 4 1.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.1 Table 17 - Footnote1  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3
Ontario 110 4 8 0.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.49.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1 Table 17 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9
Québec 104 4 4 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.8 Table 17 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0  Table 17 - Footnote2
Gentamicin British Columbia 70 1 1 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.7  Table 17 - Footnote1  Table 17 - Footnote2
Saskatchewan 78 1 1 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8  Table 17 - Footnote1  Table 17 - Footnote2
Ontario 110 1 2 1.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.2  Table 17 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9 Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9
Québec 104 1 1 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.8  Table 17 - Footnote1  Table 17 - Footnote2
Kanamycin British Columbia 70 <=8 <=8 1.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.6  Table 17 - Footnote1  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4
Saskatchewan 78 <=8 <=8 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0  Table 17 - Footnote1  Table 17 - Footnote2
Ontario 110 <=8 <=8 3.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.4  Table 17 - Footnote1  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.6
Québec 104 <=8 <=8 1.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.1  Table 17 - Footnote1  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9
Nalidixic acid British Columbia 70 2 2 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.74.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.6  Table 17 - Footnote2
Saskatchewan 78 2 4 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.3  Table 17 - Footnote2
Ontario 110 2 4 1.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.8  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.8
Québec 104 2 4 2.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.6  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.9
Streptomycin British Columbia 70 <=32 64 20.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14.3 Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.7
Saskatchewan 78 <=32 <=32 9.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.4 Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.6
Ontario 110 <=32 >64 19.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8.2 Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.9
Québec 104 <=32 <=32 5.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.8 Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9
Trimethoprim-sulfamethoxazole British Columbia 70 <=0.12 <=0.12 1.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4
Saskatchewan 78 <=0.12 <=0.12 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6  Table 17 - Footnote2
Ontario 110 <=0.12 <=0.12 7.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.3
Québec 104 <=0.12 <=0.12 1.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9
III Chloramphenicol British Columbia 70 8 8 2.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.7 Table 17 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4 Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4
Saskatchewan 78 8 8 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.3 Table 17 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3   Table 17 - Footnote2
Ontario 110 8 8 2.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.4 Table 17 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.7
Québec 104 8 8 1.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 Table 17 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.0
Sulfisoxazole British Columbia 70 <=16 >256 21.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21.4 Table 17 - Footnote2
Saskatchewan 78 <=16 >256 10.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.3 Table 17 - Footnote2
Ontario 110 <=16 >256 16.4  Table 17 - Footnote2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.16.4 Table 17 - Footnote2
Québec 104 <=16 32 7.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.7 Table 17 - Footnote2
Tetracycline British Columbia 70 <=4 >32 34.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.3 Table 17 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.1 Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.25.7
Saskatchewan 78 <=4 >32 17.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.8 Table 17 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3  Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.17.9
Ontario 110 <=4 >32 30.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.4 Table 17 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9 Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.28.2
Québec 104 <=4 >32 15.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.7 Table 17 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.0 Table 17 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12.5

Table 18. Distribution of minimum inhibitory concentrations among Salmonella from chicken
  Antimicrobial Province / region n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0,015 0,03 0,06 0,12 0,25 0,5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid British Columbia 53 <=1 >32 39.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9  Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.34.0
Saskatchewan 46 <=1 >32 13.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.6  Table 18 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13.0
Ontario 102 <=1 >32 22.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9 Table 18 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21.6
Québec 106 <=1 >32 28.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.25.5
Ceftiofur British Columbia 53 1 >8 39.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.37.7
Saskatchewan 46 1 >8 13.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.2  Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.9
Ontario 102 1 >8 22.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0 Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21.6
Québec 106 1 >8 28.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.0  Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.28.3
Ceftriaxone British Columbia 53 <=0.25 32 39.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.4  Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.18.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.8
Saskatchewan 46 <=0.25 8 13.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.87.0  Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2
Ontario 102 <=0.25 16 22.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.5  Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8.8
Québec 106 <=0.25 16 28.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.7  Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.17.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.8
Ciprofloxacin British Columbia 53 <=0.015 0.03 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.1  Table 18 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8
Saskatchewan 46 <=0.015 0.03 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.1  Table 18 - Footnote1
Ontario 102 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.90.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.8  Table 18 - Footnote1
Québec 106 <=0.015 0.03 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.2  Table 18 - Footnote1
II Ampicillin British Columbia 53 <=1 >32 39.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9  Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.39.6
Saskatchewan 46 <=1 >32 17.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.6  Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.17.4
Ontario 102 <=1 >32 31.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9  Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.31.4
Québec 106 <=1 >32 29.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9  Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.29.2
Azithromycin British Columbia 53 4 4 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.5
Saskatchewan 46 4 4 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.5
Ontario 102 4 8 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.5
Québec 106 4 8 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.2
Cefoxitin British Columbia 53 2 >32 35.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.7  Table 18 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.24.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11.3
Saskatchewan 46 2 32 10.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.2 Table 18 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.3
Ontario 102 2 32 20.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.9  Table 18 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.9
Québec 106 2 32 27.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.5  Table 18 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.7
Gentamicin British Columbia 53 0.50 1 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.9  Table 18 - Footnote1
Saskatchewan 46 0.50 1 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.2  Table 18 - Footnote1
Ontario 102 0.50 1 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.7  Table 18 - Footnote1
Québec 106 0.50 1 2.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.0  Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.8
Kanamycin British Columbia 53 <=8 <=8 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0  Table 18 - Footnote1
Saskatchewan 46 <=8 <=8 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0  Table 18 - Footnote1
Ontario 102 <=8 <=8 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0  Table 18 - Footnote1
Québec 106 <=8 <=8 0.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.99.1  Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9
Nalidixic acid British Columbia 53 4 4 3.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.8
Saskatchewan 46 4 4 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.3
Ontario 102 4 4 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9
Québec 106 4 4 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.9
Streptomycin British Columbia 53 <=32 >64 26.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.18.9
Saskatchewan 46 <=32 >64 17.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13.0
Ontario 102 <=32 >64 23.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15.7
Québec 106 <=32 >64 30.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.17.0
Trimethoprim-sulfamethoxazole British Columbia 53 <=0.12 <=0.12 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0
Saskatchewan 46 <=0.12 <=0.12 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.2
Ontario 102 <=0.12 <=0.12 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0
Québec 106 <=0.12 <=0.12 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.99.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9
III Chloramphenicol British Columbia 53 4 8 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.2 Table 18 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9
Saskatchewan 46 8 8 4.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.2 Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.3
Ontario 102 8 8 1.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.7 Table 18 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.0
Québec 106 8 8 0.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.5 Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9
Sulfisoxazole British Columbia 53 32 64 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.3
Saskatchewan 46 32 64 4.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.3
Ontario 102 32 64 2.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.9
Québec 106 32 64 5.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.7
Tetracycline British Columbia 53 <=4 >32 30.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.9 Table 18 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.30.2
Saskatchewan 46 <=4 >32 19.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.4 Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15.2
Ontario 102 <=4 >32 29.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.6 Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.28.4
Québec 106 <=4 >32 31.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.9 Table 18 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.31.1

Table 19. Distribution of minimum inhibitory concentrations among Escherichia coli from chicken
  Antimicrobial Province/region n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0,015 0,03 0,06 0,12 0,25 0,5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid British Columbia 74 8 >32 43.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.5 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.29.7 13.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 64 4 32 23.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.7 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  14.1 9.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 107 4 32 19.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.2 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12.1 7.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 128 4 32 26.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.2 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9 18.8 7.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur British Columbia 74 0.50 >8 39.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.4 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21.6 17.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 64 0.50 8 21.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Table 19 - Footnote1 14.1 7.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 107 0.50 8 18.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9.3 9.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 128 0.50 8 25.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 17.2 7.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone British Columbia 74 <=0.25 16 40.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.1 21.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 64 <=0.25 16 21.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 6.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9.4 6.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 107 <=0.25 16 18.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 19 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.6 10.3 2.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 128 <=0.25 16 26.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 19 - Footnote1 9.4 14.1 3.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin British Columbia 74 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.93.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7  Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 64 <=0.015 0.03 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 107 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 128 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin British Columbia 37 2 >32 18.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 19 - Footnote1 59.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 2 >32 19.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.1  Table 19 - Footnote1 28.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 4 >32 29.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 Table 19 - Footnote1 0.9 43.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 2 >32 18.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 19 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.  43.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin British Columbia 37 4 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  0.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin British Columbia 37 4 >32 10.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.1 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 9.5 31.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 4 4 3.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  3.1 20.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 4 4 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.5 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.6 14.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 4 8 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.3 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12.5 14.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin British Columbia 37 1 1 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.1  Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.4 5.4 6.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 1 1 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 1.6 7.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 1 1 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  3.7 8.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 1 2 4.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3  Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.1 21.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin British Columbia 37 <=8 <=8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.93.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.1 Table 19 - Footnote1 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 <=8 <=8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.87.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Table 19 - Footnote1 10.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 <=8 >64 10.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.8 Table 19 - Footnote1 14.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 <=8 >64 18.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9 Table 19 - Footnote1 0.8 18.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid British Columbia 37 2 4 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  1.4 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 2 2 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.79.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.7 3.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 2 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 1.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 2 4 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  0.8 0.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin British Columbia 37 <=32 >64 13.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.8 25.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 <=32 >64 19.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.7 31.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 <=32 >64 30.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.6 22.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 <=32 >64 36.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.17.2 28.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Trimethoprim-sulfamethoxazole British Columbia 37 <=0.12 <=0.12 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 9.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 <=0.12 0.25 7.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1 1.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 <=0.12 0.25 4.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.86.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  7.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 <=0.12 0.25 9.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 15.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol British Columbia 37 8 8 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.3 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 10.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 8 8 7.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62.5 Table 19 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.     Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 8 8 8.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.3 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.  0.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 8 8 6.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.4 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.  3.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole British Columbia 37 <=16 >256 10.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  35.1
Saskatchewan 26 <=16 >256 19.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 20.3
Ontario 86 <=16 >256 23.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  27.1
Québec 44 <=16 >256 38.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  49.2
Tetracycline British Columbia 37 <=4 >32 24.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58.1 Table 19 - Footnote1 2.7 39.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 <=4 >32 34.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.1 Table 19 - Footnote1 1.6 34.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 >32 >32 58.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.4 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  0.9 47.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 <=4 >32 47.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39.8 Table 19 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 0.8 57.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity

Table 20. Distribution of minimum inhibitory concentrations among Campylobacter from chicken
  Antimicrobial Species Province/region n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0,016 0,032 0,064 0,125 0,25 0,5 1 2 4 8 16 32 64 >64
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I  Ciprofloxacin Campylobacter coli British Columbia 7 0,125 16 42,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6  Table 20 - Footnote1  Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14,3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.28,6  Discontinuation or no surveillance activity
Ciprofloxacin Campylobacter coli Saskatchewan 3 0,125 0,125 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Ciprofloxacin Campylobacter coli Ontario 10 0,064 16 10,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0  Table 20 - Footnote1  Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10,0  Discontinuation or no surveillance activity
Ciprofloxacin Campylobacter coli Québec 3 0,25 16 33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3  Table 20 - Footnote1  Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33,3  Discontinuation or no surveillance activity
Ciprofloxacin Campylobacter jejuni British Columbia 66 0,125 0,125 4,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,5  Table 20 - Footnote1  Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,5  Discontinuation or no surveillance activity
Ciprofloxacin Campylobacter jejuni Saskatchewan 36 0,125 0,125 5,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47,2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8  Table 20 - Footnote1  Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5,6  Discontinuation or no surveillance activity
Ciprofloxacin Campylobacter jejuni Ontario 75 0,125 8 13,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13,3  Table 20 - Footnote1  Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9,3  Discontinuation or no surveillance activity
Ciprofloxacin Campylobacter jejuni Québec 76 0,125 0,25 1,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47,4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22,4  Table 20 - Footnote1  Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,3  Discontinuation or no surveillance activity
Ciprofloxacin Campylobacter spp. British Columbia 0 0 0 0,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Ciprofloxacin Campylobacter spp. Saskatchewan 1 0,125 0,125 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Ciprofloxacin Campylobacter spp. Ontario 3 4 4 100,0  Table 20 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.100,0 Table 20 - Footnote2  Discontinuation or no surveillance activity
Ciprofloxacin Campylobacter spp. Québec 0 0 0 0,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Telithromycin Campylobacter coli British Columbia 7 0,25 2 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6  Table 20 - Footnote1  Table 20 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Telithromycin Campylobacter coli Saskatchewan 3 2 2 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7  Table 20 - Footnote1  Table 20 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Telithromycin Campylobacter coli Ontario 10 2 16 10,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0 Table 20 - Footnote1 10,0 Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Telithromycin Campylobacter coli Québec 3 2 4 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Table 20 - Footnote1  Table 20 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Telithromycin Campylobacter jejuni British Columbia 66 0,5 1 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68,2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,2  Table 20 - Footnote1  Table 20 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Telithromycin Campylobacter jejuni Saskatchewan 36 0,5 1 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22,2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,6  Table 20 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8  Table 20 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Telithromycin Campylobacter jejuni Ontario 75 0,5 2 2,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,7 Table 20 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3 2,7 Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Telithromycin Campylobacter jejuni Québec 76 1 2 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38,2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13,2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,3 Table 20 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,9  Table 20 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Telithromycin Campylobacter spp. British Columbia 0 0 0 0,0  Table 20 - Footnote1  Table 20 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Telithromycin Campylobacter spp. Saskatchewan 1 0,25 0,25 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Table 20 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Telithromycin Campylobacter spp. Ontario 3 1 1 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Table 20 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Telithromycin Campylobacter spp. Québec 0 0 0 0,0  Table 20 - Footnote1  Table 20 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II  Azithromycin Campylobacter coli British Columbia 7 0,032 0,125 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Azithromycin Campylobacter coli Saskatchewan 3 0,125 0,125 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Azithromycin Campylobacter coli Ontario 10 0,064 > 64 20,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0  Table 20 - Footnote1  Table 20 - Footnote2 20,0
Azithromycin Campylobacter coli Québec 3 0,125 0,125 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Azithromycin Campylobacter jejuni British Columbia 66 0,064 0,064 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39,4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,5  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Azithromycin Campylobacter jejuni Saskatchewan 36 0,064 0,064 2,8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,6  Table 20 - Footnote1  Table 20 - Footnote2 2,8
Azithromycin Campylobacter jejuni Ontario 75 0,064 0,064 5,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3  Table 20 - Footnote1  Table 20 - Footnote2 5,3
Azithromycin Campylobacter jejuni Québec 76 0,064 0,125 7,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36,8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,9  Table 20 - Footnote1  Table 20 - Footnote2 7,9
Azithromycin Campylobacter spp. British Columbia 0 0 0 0,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Azithromycin Campylobacter spp. Saskatchewan 1 0,032 0,032 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Azithromycin Campylobacter spp. Ontario 3 0,125 0,125 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Azithromycin Campylobacter spp. Québec 0 0 0 0,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Clindamycin Campylobacter coli Saskatchewan 7 0,25 1 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Clindamycin Campylobacter coli Ontario 3 0,25 0,5 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Clindamycin Campylobacter coli Québec 10 0,25 16 30,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0  Table 20 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.20,0 Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Table 20 - Footnote2  Discontinuation or no surveillance activity
Clindamycin Campylobacter jejuni British Columbia 3 1 8 33,3  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3  Table 20 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33,3 Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Clindamycin Campylobacter jejuni Saskatchewan 66 0,125 0,25 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34,8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,5  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Clindamycin Campylobacter jejuni Ontario 36 0,125 0,25 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27,8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8  Table 20 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Clindamycin Campylobacter jejuni Québec 75 0,125 0,25 1,3  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,7  Table 20 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,3 Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Clindamycin Campylobacter jejuni Maritimes 76 0,125 0,5 1,3  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3 Table 20 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,3 Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Clindamycin Campylobacter spp. British Columbia 0 0 0 0,0  Discontinuation or no surveillance activity  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Clindamycin Campylobacter spp. Saskatchewan 1 0,25 0,25 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Clindamycin Campylobacter spp. Ontario 3 0,125 0,25 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Clindamycin Campylobacter spp. Québec 0 0 0 0,0  Discontinuation or no surveillance activity  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Erythromycin Campylobacter coli British Columbia 7 0,25 2 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Erythromycin Campylobacter coli Saskatchewan 3 1 2 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Erythromycin Campylobacter coli Ontario 10 1 > 64 20,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0  Table 20 - Footnote1  Table 20 - Footnote2 20,0
Erythromycin Campylobacter coli Québec 3 2 2 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Erythromycin Campylobacter jejuni British Columbia 66 0,25 0,5 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19,7  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Erythromycin Campylobacter jejuni Saskatchewan 36 0,25 0,5 2,8  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8  Table 20 - Footnote1  Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,8  Discontinuation or no surveillance activity
Erythromycin Campylobacter jejuni Ontario 75 0,25 0,5 5,3  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,0  Table 20 - Footnote1  Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,3 4,0
Erythromycin Campylobacter jejuni Québec 76 0,5 2 7,9  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43,4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9,2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,6  Table 20 - Footnote1  Table 20 - Footnote2 7,9
Erythromycin Campylobacter spp. British Columbia 0 0 0 0,0  Discontinuation or no surveillance activity  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Erythromycin Campylobacter spp. Saskatchewan 1 0,125 0,125 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Erythromycin Campylobacter spp. Ontario 3 1 1 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Erythromycin Campylobacter spp. Québec 0 0 0 0,0  Discontinuation or no surveillance activity  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
II  Gentamicin Campylobacter coli British Columbia 7 0,5 1 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin Campylobacter coli Saskatchewan 3 1 1 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin Campylobacter coli Ontario 10 0,5 1 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin Campylobacter coli Québec 3 1 2 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin Campylobacter jejuni British Columbia 66 1 1 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin Campylobacter jejuni Saskatchewan 36 1 1 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27,8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72,2  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin Campylobacter jejuni Ontario 75 0,5 1 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.49,3  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin Campylobacter jejuni Québec 76 0,5 1 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43,4  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin Campylobacter spp. British Columbia 0 0 0 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin Campylobacter spp. Saskatchewan 1 1 1 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin Campylobacter spp. Ontario 3 1 2 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin Campylobacter spp. Québec 0 0 0 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid Campylobacter coli British Columbia 7 16 > 64 42,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3 Table 20 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14,3 Table 20 - Footnote2 28,6
Nalidixic acid Campylobacter coli Saskatchewan 3 8 16 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Nalidixic acid Campylobacter coli Ontario 10 8 > 64 10,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0 Table 20 - Footnote1  Table 20 - Footnote2 10,0
Nalidixic acid Campylobacter coli Québec 3 8 > 64 33,3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3  Table 20 - Footnote1  Table 20 - Footnote2 33,3
Nalidixic acid Campylobacter jejuni British Columbia 66 ≤ 4 8 4,5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31,8  Table 20 - Footnote1  Table 20 - Footnote2 4,5
Nalidixic acid Campylobacter jejuni Saskatchewan 36 ≤ 4 8 5,6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77,8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7  Table 20 - Footnote1  Table 20 - Footnote2 5,6
Nalidixic acid Campylobacter jejuni Ontario 75 ≤ 4 > 64 13,3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24,0  Table 20 - Footnote1  Table 20 - Footnote2 13,3
Nalidixic acid Campylobacter jejuni Québec 76 ≤ 4 8 1,3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,1  Table 20 - Footnote1  Table 20 - Footnote2 1,3
Nalidixic acid Campylobacter spp. British Columbia 0 0 0 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Nalidixic acid Campylobacter spp. Saskatchewan 1 8 8 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Nalidixic acid Campylobacter spp. Ontario 3 > 64 > 64 100,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 20 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33,3 Table 20 - Footnote2 66,7
Nalidixic acid Campylobacter spp. Québec 0 0 0 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
III  Florfenicol Campylobacter coli British Columbia 7 1 2 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,9  Table 20 - Footnote1  Discontinuation or no surveillance activity
Florfenicol Campylobacter coli Saskatchewan 3 1 1 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Discontinuation or no surveillance activity
Florfenicol Campylobacter coli Ontario 10 1 2 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0  Table 20 - Footnote1  Discontinuation or no surveillance activity
Florfenicol Campylobacter coli Québec 3 1 2 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3  Table 20 - Footnote1  Discontinuation or no surveillance activity
Florfenicol Campylobacter jejuni British Columbia 66 1 1 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.90,9  Table 20 - Footnote1  Discontinuation or no surveillance activity
Florfenicol Campylobacter jejuni Saskatchewan 36 1 1 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,8  Table 20 - Footnote1  Discontinuation or no surveillance activity
Florfenicol Campylobacter jejuni Ontario 75 1 1 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,7  Table 20 - Footnote1  Discontinuation or no surveillance activity
Florfenicol Campylobacter jejuni Québec 76 1 2 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,5  Table 20 - Footnote1  Discontinuation or no surveillance activity
Florfenicol Campylobacter spp. British Columbia 0 0 0 0,0  Discontinuation or no surveillance activity  Table 20 - Footnote1  Discontinuation or no surveillance activity
Florfenicol Campylobacter spp. Saskatchewan 1 1 1 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Discontinuation or no surveillance activity
Florfenicol Campylobacter spp. Ontario 3 1 1 0,0  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Discontinuation or no surveillance activity
Florfenicol Campylobacter spp. Québec 0 0 0 0,0  Discontinuation or no surveillance activity  Table 20 - Footnote1  Discontinuation or no surveillance activity
Tetracycline Campylobacter coli British Columbia 7 1 64 28,6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,9  Table 20 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14,3 Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14,3
Tetracycline Campylobacter coli Saskatchewan 3 0,5 > 64 33,3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3  Table 20 - Footnote1  Table 20 - Footnote2 33,3
Tetracycline Campylobacter coli Ontario 10 0,5 > 64 40,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,0  Table 20 - Footnote1  Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10,0 30,0
Tetracycline Campylobacter coli Québec 3 8 > 64 33,3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Table 20 - Footnote1  Table 20 - Footnote2 33,3
Tetracycline Campylobacter jejuni British Columbia 66 0,25 64 25,8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,5  Table 20 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,5 Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.16,7 7,6
Tetracycline Campylobacter jejuni Saskatchewan 36 32 > 64 52,8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22,2  Table 20 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5,6 Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.22,2 25,0
Tetracycline Campylobacter jejuni Ontario 75 32 > 64 50,7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,7  Table 20 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6,7 Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.16,0 28,0
Tetracycline Campylobacter jejuni Québec 76 64 > 64 64,5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3  Table 20 - Footnote1  Table 20 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.25,0 39,5
Tetracycline Campylobacter spp. British Columbia 0 0 0 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Tetracycline Campylobacter spp. Saskatchewan 1 0,5 0,5 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100,0  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Tetracycline Campylobacter spp. Ontario 3 0,25 0,25 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,7  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
Tetracycline Campylobacter spp. Québec 0 0 0 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 20 - Footnote1  Table 20 - Footnote2  Discontinuation or no surveillance activity
IV   Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity

Table 21. Distribution of minimum inhibitory concentrations among Escherichia coli from pork
  Antimicrobial Province/region n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0,015 0,03 0,06 0,12 0,25 0,5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid British Columbia 37 4 32 10.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.5 Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.7 Table 21 - Footnote2 8.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 4 8 3.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.4 Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2 3.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 4 8 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.2 Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3 Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 4 8 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.3 Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 21 - Footnote1  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur British Columbia 37 0.50 8 10.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.4Table 21 - Footnote2 5.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 0.50 0.50 3.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote1  Table 21 - Footnote2 3.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 0.25 0.50 1.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.2 Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 0.50 0.50 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Table 21 - Footnote1  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 21 - Footnote1  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone British Columbia 37 <=0.25 16 10.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.86.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Table 21 - Footnote1  Table 21 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 <=0.25 <=0.25 3.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.2  Table 21 - Footnote1  Table 21 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 <=0.25 <=0.25 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 21 - Footnote1  Table 21 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 <=0.25 <=0.25 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Table 21 - Footnote1  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 21 - Footnote1  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin British Columbia 37 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.4  Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8 Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Table 21 - Footnote1  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin British Columbia 37 2 >32 18.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Table 21 - Footnote1  Table 21 - Footnote2 18.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 2 >32 19.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.2  Table 21 - Footnote1  Table 21 - Footnote2 19.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 4 >32 29.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39. Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Table 21 - Footnote1  Table 21 - Footnote2 29.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 2 >32 18.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Table 21 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3  Table 21 - Footnote2 18.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 21 - Footnote1  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin British Columbia 37 4 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7  Table 21 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8  Table 21 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 21 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin British Columbia 37 4 >32 10.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.8  Table 21 - Footnote2 10.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 4 4 3.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2 3.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 4 4 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3 Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 4 8 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin British Columbia 37 1 1 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.4  Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 1 1 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 1 1 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.87.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 1 2 4.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.6  Table 21 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3 Table 21 - Footnote2 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 21 - Footnote1  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin British Columbia 37 <=8 <=8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 21 - Footnote1  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 <=8 <=8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 21 - Footnote1  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 <=8 >64 10.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 21 - Footnote1  Table 21 - Footnote2 10.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 <=8 >64 18.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 21 - Footnote1  Table 21 - Footnote2 18.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 21 - Footnote1  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid British Columbia 37 2 4 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 2 2 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.7  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 2 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 2 4 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin British Columbia 37 <=32 >64 13.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.86.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.7 Table 21 - Footnote2 10.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 <=32 >64 19.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.7 Table 21 - Footnote2 11.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 <=32 >64 30.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15.1 Table 21 - Footnote2 15.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 <=32 >64 36.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13.6 Table 21 - Footnote2 22.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Trimethoprim-sulfamethoxazole British Columbia 37 <=0.12 <=0.12 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 <=0.12 0.25 7.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.88.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2 7.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 <=0.12 0.25 4.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2  Table 21 - Footnote2 4.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 <=0.12 0.25 9.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 21 - Footnote2 9.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol British Columbia 37 8 8 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.1 Table 21 - Footnote1  Table 21 - Footnote2 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 8 8 7.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.8 Table 21 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.8 Table 21 - Footnote2 3.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 8 8 8.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.7 Table 21 - Footnote2 3.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 8 8 6.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3 Table 21 - Footnote2 4.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 21 - Footnote1  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole British Columbia 37 <=16 >256 10.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  10.8 Table 21 - Footnote2
Saskatchewan 26 <=16 >256 19.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  19.2 Table 21 - Footnote2
Ontario 86 <=16 >256 23.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  23.3 Table 21 - Footnote2
Québec 44 <=16 >256 38.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  38.6 Table 21 - Footnote2
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Tetracycline British Columbia 37 <=4 >32 24.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.7 Table 21 - Footnote1  Table 21 - Footnote2 24.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 26 <=4 >32 34.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.4 Table 21 - Footnote1  Table 21 - Footnote2 34.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 86 >32 >32 58.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.7 Table 21 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2  Table 21 - Footnote2 58.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 44 <=4 >32 47.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.3 Table 21 - Footnote1  Table 21 - Footnote2 47.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Maritimes 0 0 0 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Table 21 - Footnote1  Table 21 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity

Table 22. Distribution of minimum inhibitory concentrations in Salmonella from turkey
  Antimicrobial Province/region n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0,015 0,03 0,06 0,12 0,25 0,5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid British Columbia 27 <=1 >32 29.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.7 Table 22 - Footnote2 25.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 <=1 16 5.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6  Table 22 - Footnote2 5.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 <=1 >32 20.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint. Table 22 - Footnote2 20.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 <=1 >32 29.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8 Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0  Table 22 - Footnote2 29.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur British Columbia 27 1 >8 33.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.4 Table 22 - Footnote2 25.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 1 1 5.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.8  Table 22 - Footnote1  Table 22 - Footnote2 5.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 1 >8 20.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote2 20.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 1 >8 29.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.8  Table 22 - Footnote1   Table 22 - Footnote2 29.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone British Columbia 27 <=0.25 16 37.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.4 Table 22 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.18.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 <=0.25 <=0.25 5.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.4  Table 22 - Footnote1  Table 22 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 <=0.25 32 20.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.79.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1  Table 22 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 <=0.25 32 29.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1  Table 22 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin British Columbia 27 <=0.015 0.03 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8  Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 <=0.015 0.03 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.7  Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 <=0.015 0.03 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 <=0.015 0.03 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin British Columbia 27 <=1 >32 37.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote1  Table 22 - Footnote2 37.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 <=1 >32 11.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote1  Table 22 - Footnote2 11.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 <=1 >32 25.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote1  Table 22 - Footnote2 25.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 <=1 >32 39.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1  Table 22 - Footnote2 39.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin British Columbia 27 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.88.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7  Table 22 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 4 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22.2  Table 22 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 4 8 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 2.3 Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 4 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin British Columbia 27 2 32 22.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.22.2 Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 4 4 5.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote2 5.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 2 >32 20.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.5 Table 22 - Footnote2 15.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 4 >32 29.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.9 Table 22 - Footnote2 23.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin British Columbia 27 0.50 1 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4   Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 0.50 >16 16.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote2 16.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 0.50 1 6.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote2 6.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 0.50 1 2.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote1  Table 22 - Footnote2 2.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin British Columbia 27 <=8 <=8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1  Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 <=8 <=8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6 Table 22 - Footnote1  Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 <=8 <=8 4.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1  Table 22 - Footnote2 4.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 <=8 <=8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint. Table 22 - Footnote1  Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid British Columbia 27 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4  Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.77.8  Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.86.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5  Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin British Columbia 27 <=32 >64 48.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.4 Table 22 - Footnote2 40.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 >64 >64 50.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0  Table 22 - Footnote2 50.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 <=32 >64 20.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.79.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.8Table 22 - Footnote2 13.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 <=32 >64 29.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.8 Table 22 - Footnote2 21.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Trimethoprim-sulfamethoxazole British Columbia 27 <=0.12 <=0.12 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 <=0.12 0.25 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6  Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 <=0.12 <=0.12 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.90.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3  Table 22 - Footnote2 2.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 <=0.12 0.25 3.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.86.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote2 3.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol British Columbia 27 8 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.3 Table 22 - Footnote1  Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 8 8 5.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.7 Table 22 - Footnote1  Table 22 - Footnote2 5.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 8 >32 11.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.5 Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.   Table 22 - Footnote2 11.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 8 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.4 Table 22 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0  Table 22 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole British Columbia 27 32 128 7.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7 7.4 Table 22 - Footnote2
Saskatchewan 18 >256 >256 50.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.7 50.0 Table 22 - Footnote2
Ontario 44 32 >256 11.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.5 11.4 Table 22 - Footnote2
Québec 51 32 >256 15.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  15.7 Table 22 - Footnote2
Tetracycline British Columbia 27 >32 >32 51.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.1 Table 22 - Footnote1  Table 22 - Footnote2 51.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 18 >32 >32 66.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33.3 Table 22 - Footnote1  Table 22 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.6 61.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 44 <=4 >32 18.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.8 Table 22 - Footnote1  Table 22 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.5 13.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 51 <=4 >32 23.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.5 Table 22 - Footnote1  Table 22 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.0 21.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV 0 0 0 0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity

Table 23. Distribution of minimum inhibitory concentrations in Escherichia coli from turkey
  Antimicrobial Province/region n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0,015 0,03 0,06 0,12 0,25 0,5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid British Columbia 101 4 32 15,8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18,8 Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9,9 Table 23 - Footnote2 5,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 81 4 8 4,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,0 Table 23 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,9 Table 23 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 152 4 32 11,2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,4 Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9,2 Table 23 - Footnote2 2,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 170 4 32 12,4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27,1 Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8,8 Table 23 - Footnote2 3,5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur British Columbia 101 0,50 8 12,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,0 Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8,9 Table 23 - Footnote2 4,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 81 0,25 0,50 3,7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44,4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2  Table 23 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,5 Table 23 - Footnote2 1,2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 152 0,50 1 8,6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3  Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8,6 Table 23 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 170 0,50 8 11,2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,8  Table 23 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,7 Table 23 - Footnote2 6,5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone British Columbia 101 ≤ 0,25 8 13,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83,2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,0 Table 23 - Footnote1  Table 23 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5,0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6,9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 81 ≤ 0,25 ≤ 0,25 3,7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96,3  Table 23 - Footnote1  Table 23 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 152 ≤ 0,25 0,50 9,2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.88,8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7 Table 23 - Footnote1  Table 23 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3,3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5,3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0,7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 170 ≤ 0,25 8 11,2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.88,2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,6 Table 23 - Footnote1  Table 23 - Footnote2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3,5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5,9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin British Columbia 101 ≤ 0,015 ≤ 0,015 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,0  Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,0  Table 23 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 81 ≤ 0,015 ≤ 0,015 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2  Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,5  Table 23 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 152 ≤ 0,015 ≤ 0,015 0,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95,4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,0  Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3  Table 23 - Footnote2 0,7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 170 ≤ 0,015 ≤ 0,015 0,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,6 Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2  Table 23 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin British Columbia 101 2 > 32 30,7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,8  Table 23 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,0 Table 23 - Footnote2 29,7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 81 2 > 32 24,7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13,6  Table 23 - Footnote1  Table 23 - Footnote2 24,7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 152 2 > 32 30,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11,8  Table 23 - Footnote1  Table 23 - Footnote2 30,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 170 4 > 32 37,6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2 Table 23 - Footnote1  Table 23 - Footnote2 37,6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin British Columbia 101 4 4 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20,8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,9  Table 23 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 81 4 4 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,4  Table 23 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 152 4 8 1,3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7 1,3 Table 23 - Footnote2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 170 4 4 0,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,6  Table 23 - Footnote2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin British Columbia 101 4 > 32 14,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,9 Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2,0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,0 Table 23 - Footnote2 10,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 81 4 8 3,7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7,4 Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1,2 Table 23 - Footnote2 2,5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 152 4 32 10,5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48,7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12,5 Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,6 Table 23 - Footnote2 5,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 170 4 32 11,8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28,8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10,6 Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4,1 Table 23 - Footnote2 7,6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin British Columbia 101 1 2 6,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15,8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,9  Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3,0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3,0 Table 23 - Footnote2 4,0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 81 1 16 13,6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16,0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,2 Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4,9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3,7 Table 23 - Footnote2 9,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ontario 152 1 > 16 15,8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11,2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66,4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7 Table 23 - Footnote1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0,7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,0 Table 23 - Footnote2 13,8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Québec 170 1 2 9,4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15,3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8,2  Table 23 - Footnote1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2,4 Table 23 - Footnote2 7,1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin British Columbia 101 ≤ 8 16 9,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89,1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1,0 Table 23 - Footnote1  Table 23 - Footnote2 9,9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Saskatchewan 81 ≤ 8 > 64 12,3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81,5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6,2 Table 23 - Footnote1  Table 23 - Footnote2 12,3  Discontinuation or no surveillance activity &nb